Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 5/20 | 0.36 |
| ▸ | CDK6 | Q00534 | 3/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | WEE1 | P30291 | 10/20 | 0.32 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.32 |
| ▸ | CCND1 | P24385 | 2/20 | 0.32 |
| ▸ | CDK2 | P24941 | 2/20 | 0.32 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.32 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15041640 | 0.93 | CDK4 (0.36) | CDK4CDK6JAK3WEE1CCNA2 | |
| SCHEMBL15036493 | 0.80 | CDK4 (0.39) | CDK4CDK6JAK3CCNA2CCND1 | |
| SCHEMBL15035073 | 0.79 | CDK4 (0.39) | CDK4CDK6JAK3CCNA2CCND1 | |
| SCHEMBL15035843 | 0.78 | CDK4 (0.38) | CDK4CDK6JAK3WEE1PKMYT1 | |
| SCHEMBL15041732 | 0.76 | FGFR1 (0.39) | CDK4CDK6JAK3WEE1CCNA2 | |
| SCHEMBL15034962 | 0.75 | CDK4 (0.36) | CDK4CDK6JAK3WEE1CCNA2 | |
| SCHEMBL15036315 | 0.75 | FGFR1 (0.40) | CDK4CDK6WEE1CCNA2CCND1 | |
| SCHEMBL15034855 | 0.73 | CDK4 (0.37) | CDK4CDK6JAK3WEE1CCNA2 | |
| SCHEMBL15036288 | 0.73 | CDK4 (0.39) | CDK4CDK6CCNA2CCND1CDK2 | |
| SCHEMBL15035723 | 0.73 | CDK4 (0.39) | CDK4CDK6JAK3CCNA2CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130252967-A1 | 8-(SULFONYLBENZYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252967-A1 | 8-(SULFONYLBENZYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | PAK2, PAK3, PAK6 | CDK4 441/4885CDK6 411/4885JAK3 525/4885 |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | CDK4 404/4885CDK6 435/4885JAK3 1901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.